77 Decoding diabetes treatment pathways: AI-driven insights from real-world data Authors: Polina Kukhareva, Julio Facelli Published: 2026 ABSTRACT AbstractObjectives/Goals: To identify real-world type 2 diabetes (T2D) treatment pathways and evaluate whether AI models trained on electronic health record (EHR) medication histories can improve prediction of glycemic outcomes in routine clinical practice. Methods/Study Population: We conducted a retrospective cohort study using de-identified EHR data from the TriNetX Research Network (>3 M adults with T2D, 2019–2024). Medication, laboratory, and demographic data were standardized in PostgreSQL on the University of Utah CHPC. Patients with T1D, pregnancy, or incomplete follow-up were excluded. Longitudinal medication sequences were clustered using hierarchical agglomerative methods to identify treatment trajectories. Transformer-based models incorporating full prescription histories were trained to predict 6-month HbA1c, and performance (RMSE) was assessed overall and across demographic groups. Results/Anticipated Results: Among >3 M adults with T2D, we identified 40 distinct treatment clusters representing mono-, dual-, complex-, GLP-1–based, and variant pathways. GLP-1/GIP agents were typically used as 2nd–3rd-line therapy after metformin or SGLT2i and produced the largest BMI and HbA1c improvements. Baseline XGBoost models using EHR features predicted 6-month HbA1c with RMSE ≈ 0.72. The last HbA1c value was the most predictive feature, though additional labs and demographics modestly improved accuracy. Ongoing work is developing transformer models to capture longitudinal patterns and medication history effects. Discussion/Significance of Impact: National EHR networks can support development of trustworthy, fairness-aware AI to model diabetes pharmacotherapy. Insights reveal disparities in advanced therapy uptake and inform equitable decision-support design.